Effect of the replacement parameter . by Fynn Bachmann (21409831)

S1 File - by Kathleen Kristensen (17525457)

“…., participant reported difficulty in accessing syringes and naloxone) among PWID participating in a longitudinal study conducted through the University of Illinois-Chicago’s Community Outreach Intervention Projects field sites during the COVID-19 pandemic.…”

Chicago COVID-19 mitigation policy timeline. by Kathleen Kristensen (17525457)

“…., participant reported difficulty in accessing syringes and naloxone) among PWID participating in a longitudinal study conducted through the University of Illinois-Chicago’s Community Outreach Intervention Projects field sites during the COVID-19 pandemic.…”

Micelle and Inverse Micelle Structure Driven Viscoelasticity and Phase Separation in 2‑Isobutoxyethanol–Water Mixtures: Insights from All-Atom Simulations by Mayank Dixit (7879364)

“…Dynamical properties show a pronounced slowdown of IBE self-diffusion with decreasing the mole fraction of 2-isobutoxyethanol (<i>x</i>_IBE). …”

Micelle and Inverse Micelle Structure Driven Viscoelasticity and Phase Separation in 2‑Isobutoxyethanol–Water Mixtures: Insights from All-Atom Simulations by Mayank Dixit (7879364)

“…Dynamical properties show a pronounced slowdown of IBE self-diffusion with decreasing the mole fraction of 2-isobutoxyethanol (<i>x</i>_IBE). …”

Analysis of DCX⁺ cells showing migratory morphology (cells with small, oval/fusiform cell soma – less than 9 µm – and an unbranched leading process) in the amygdala of a... by Marco Ghibaudi (16701750)

Descriptive statistics. by Yintu Bao (12113769)

“…The analysis reveals that the SHRR program significantly reduces travel frequency, likely due to improved local accessibility that decreases the need for frequent trips. …”

Variable description. by Yintu Bao (12113769)

“…The analysis reveals that the SHRR program significantly reduces travel frequency, likely due to improved local accessibility that decreases the need for frequent trips. …”

Village characteristics. by Yintu Bao (12113769)

“…The analysis reveals that the SHRR program significantly reduces travel frequency, likely due to improved local accessibility that decreases the need for frequent trips. …”

Research data 2. by Yintu Bao (12113769)

“…The analysis reveals that the SHRR program significantly reduces travel frequency, likely due to improved local accessibility that decreases the need for frequent trips. …”

Spaceflight in microgravity reduces sGAG content in the femoral head and distal epiphysis. by Rukmani Cahill (20939813)

<b>Data for opposing effects</b><b> of maize straw and its biochar on soil N</b>_{<strong>2</strong>}<b>O emissions</b><b> </b><b>by mediating microbial nitrification and d... by MOULIANG XIAO (21266015)

“…However, biochar addition (5 t C ha⁻¹) reduced available N, i.e., 11.1–13.9% for NH₄⁺, 11.0–14.8% for NO₃⁻ and 13.8–16.6% WSON, and decreased the abundances of nitrification/denitrification genes (39.0–44.6% for AOB <i>amoA</i>, 29.5–35.5% for <i>nirK</i>, 24.4–31.8% for <i>nirS</i>) and associated genera <i>Nitrosospira</i>, <i>Mesorhizobium</i>, <i>Bradyrhizobium</i>, <i>Rhizobium</i>, <i>Pseudomonas</i>, and <i>Cupriavidus</i>. …”

Infection of CD 34 by Ancy Joseph (5634794)

“…<p><b>+</b><b> humanized mice resulted in decrease in pathogenicity in CTCF Infected mice.</b> A. …”

Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”